

Skanttr Lifescience supplies Sacubitril Valsartan Complex, manufactured under stringent process control to meet ICH and global pharmacopoeial standards for cardiovascular formulations. Each batch ensures assay precision, consistent crystallinity, and complete trace documentation for smooth submissions across regulated markets.
Preferred by formulation and finished-dose manufacturers worldwide, our complex is optimized for ARNI-based oral dosage forms. We promise dependable purity, reproducibility, and data-backed performance throughout your product lifecycle.
WHO-GMP / ISO / ICH Q7 compliance
Exports Worldwide
Integrated production unit in Gujarat, India
Developing cardiovascular therapies demands APIs that consistently meet the highest standards of purity, uniformity, and reproducibility. Here’s how we ensure that every batch performs reliably:
Consistency Across Batches
Controlled synthesis ensures reproducible purity and performance.
Documentation Ready for Submission
Comprehensive data packages following ICH and pharmacopoeial standards
Formulation-Tailored Grades
Particle size and complexation ratio customized for oral dosage forms.
Dependable Supply Network
Flexible capacity and reliable logistics ensure uninterrupted deliveries.
Our Sacubitril Valsartan Complex is developed using controlled crystallization and analytical validation to ensure therapeutic integrity.
| Test | Specification |
|---|---|
| Description | White to off-white crystalline powder |
| Identification | IR / HPLC as per in-house specification |
| Assay | ≥ 99.0% (combined content) |
| Related Substances | ≤ 0.5% total impurities |
| Loss on Drying | ≤ 0.5% |
| Residual Solvents | Within ICH Q3C limits |
| Heavy Metals | ≤ 10 ppm |
Note: Specifications may be adjusted to align with your formulation or regulatory filing needs.
At Skanttr, every step is engineered for precision and reproducibility bridging lab validation with scalable commercial production:
Controlled chemical complexation using validated methods.
Multi-step filtration and crystallization for impurity reduction.
Consistent particle size distribution to match dosage form.
Routine testing to confirm structure and assay accuracy.
Nitrogen-sealed containers to maintain potency during storage and shipping.
Our logistics and storage practices safeguard API integrity from lab-scale batches to full commercial supply:
R&D packs to multi-kilogram batches
Double-lined HDPE or fiber drums with a moisture barrier
36 months under defined storage
Store below 25°C, away from humidity and light
Typically 3–5 weeks, depending on documentation requirements
We understand that developing cardiovascular formulations requires precision, reliability, and shared accountability in every stage of development:
Our scientists fine-tune synthesis routes and analytical parameters to achieve the right balance between assay, crystallinity, and bioavailability, ensuring your ARNI formulations perform exactly as intended.
We maintain consistent specifications and quality controls as your project evolves from lab validation to commercial supply.
We prepare complete, audit-ready data packages aligned with ICH and pharmacopoeial guidelines – helping you move seamlessly through US, EU, or emerging market filings.
Our technical specialists collaborate closely with your team, offering analytical guidance, compatibility checks, and dissolution support to refine your formulation.
Our Sacubitril Valsartan Complex supports pharmaceutical developers across therapeutic areas:
We follow a structured, transparent engagement model to make collaboration effortless:
Share your formulation or project details
Receive specifications and a tailored quotation
Approve technical parameters and initiate production
Delivery followed by post-supply analytical and technical support
Secure high-purity API with full documentation and expert support for every stage of your formulation.
Solubility is influenced by particle size, complexation ratio, and residual solvent content. Optimizing these parameters improves dissolution and bioavailability.
Uniform particle size and flow properties reduce content variability during blending, ensuring consistent dosage in each unit.
Yes, factors such as pH, moisture sensitivity, and interaction with stabilizers or fillers can affect potency and dissolution. Pre-formulation testing helps identify the optimal excipient matrix.


WhatsApp us